Clinical trial NCT06856486: Acute Intervention with Sulforaphane-Smart®
Official title: Sulforaphane-Smart® on Lipid and Glucose Metabolism, Inflammation, Adiposity and Microbiome of Overweight Adults "SANO"
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: EARLY_PHASE1
Conditions: Healthy
Keywords: Glucosinolates
Isothiocyanates
Sulforaphane
bioavailability
Lead sponsor: Universidad de Murcia
Sponsor class: OTHER
Collaborators: name: Ingredalia Company
name: Spanish National Research Council (CEBAS-CSIC)
First posted: 2025-03-04
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The Sulforaphane-Smartt® formula is a pill, patented by the company INGREDALIA, prepared with broccoli by-products which have been concentrated and enriched in glucosinolates/isothiocyanates (GLS/ITCs).

The goal of this intervention study with the Sulforaphane-Smartt® formula is to study the bioavailability of the bioactive compounds in normal weight and overweight adults. The main questions it aims to answer are:

* Determine the absorption curve of the bioactive compounds (GLS/ITCs).
* Analyze the metabolites in plasma and urine of the GLS/ITCs to know the bioavailability.

This acute intervention is designed to take a single fasting dose of Sulforaphan-Smart®, collecting plasma and urine samples to study free and conjugated metabolites of GLS/ITC.

There is not a comparison group, since the acute intervention study with the Sulforaphane-Smart® is designed to determine the bioavailability of the bioactive compounds (GLS/ITCs).

Detailed description: Sulforaphan-Smart® is a formula patented by the company INGREDALA (patented by INGREDALIA: EP3123874B1). This clinical trial will provide information about the bioavailability of the bioactive compounds of this formula (GLS/ITCs). The results of this research project will give us the possibility of obtaining a nutraceutical product based on the increasing the technology readiness level (TRL) from the current TRL5 to TRL6-7.

An acute intervention study will be conducted with 20 participants, normal-weight and overweight volunteers of both sexes, to evaluate the bioavailability and the absorption curve of the GSL/ITCs by the analysis of metabolites in urine and blood. These metabolites are considered biomarkers of intake and will allow to study the bioavailability of the bioactive compounds of the Sulforaphan-Smart® formula.

Participants will be informed about the study design and activities and will signed the informed consent. They will follow a diet free of Cruciferous during 72 h before the beginning of the study, as washout period. After that participants will take a single dose of Sulforaphane-Smart® pill on a fasting regimen. To evaluate the bioavailability of the bioactive compounds (GLS/ITCs) blood samples will be withdrawn at 0, 6 and 24 h, whereas urine samples will be collected at 0, 6 and 24 h after ingestion of Sulforaphan-Smart® pill.

Free and conjugated metabolites will be analysed in plasma and urine by UHPLC-QqQ-MS/MS following their fragmentation patterns, with the aim to evaluate the bioavailability of the GSL/ITCs of the Sulforaphan-Smart® formula.

Eligibility criteria: Inclusion Criteria:

* BMI: normal weight or overweight volunteers
* No digestive or intestinal diseases
* Age between 20 and 45 years old
* Not having antibiotics during the previous three months
* Not having pharmacological treatment
* Not being smokers
* Not following restrictive diets (vegetarian/vegan diet) or nutritional supplement

Exclusion Criteria:

* BMI: low weight and obesity
* Age different from that required
* Digestive or intestinal diseases
* Having antibiotics during the previous three months
* Having pharmacological treatments
* Following restrictive diets (vegetarian/vegan diet) or nutritional supplement
* Smoker
* Menopause

Primary outcomes:
measure: Characterization of free and conjugated metabolites of GLs/ITCs in urine and plasma at the beginning of the intervention (Time 0 hours)
timeFrame: Analysis of metabolites of GSL/ITCs before intake the Sulforaphane-Smart pill.
measure: Characterization of free and conjugated metabolites of GLs/ITCs in urine and plasma after 6 hours of the intake of pill (Time 6 hours)
timeFrame: Analysis of metabolites of GSL/ITCs after 6 hours taking the Sulforaphane-Smart pill.
measure: Characterization of free and conjugated metabolites of GLs/ITCs in urine and plasma after 24 hours of the intake of pill (Time 24 hours)
timeFrame: Analysis of metabolites of GSL/ITCs after 24 hours taking the Sulforaphane-Smart pill.
Secondary outcomes:
Other outcomes:
Locations:
city: Murcia
country: Spain
facility: Edificio Pleyades-Vitalys 5ª y 6ª planta, Campus Universitario, Espinardo
Study officials:
affiliation: Universidad de Murcia
name: Rocío González Barrio
role: PRINCIPAL_INVESTIGATOR
affiliation: Universidad de Murcia
name: María Jesús Periago Castón
role: PRINCIPAL_INVESTIGATOR
References: